Quick Answer
ENDRA Life Sciences Inc. reported Net Income Loss of -$7.03 million for the year ending 2025.
- ENDRA Life Sciences Inc. showed an increase of +38.9% in Net Income Loss from 2024 to 2025.
- This data is from ENDRA Life Sciences Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2016: -$379.5 thousand | Q2 2016: -$729.1 thousand | Q3 2016: -$977.9 thousand | Q1 2017: -$741.6 thousand | Q2 2017: -$1.43 million | Q3 2017: -$908.9 thousand | Q1 2018: -$2.83 million | Q2 2018: -$1.85 million | Q3 2018: -$2.76 million | Q1 2019: -$2.75 million | Q2 2019: -$2.33 million | Q3 2019: -$3.41 million | Q1 2020: -$3.32 million | Q2 2020: -$2.89 million | Q3 2020: -$3.26 million | Q1 2021: -$2.27 million | Q2 2021: -$3.20 million | Q3 2021: -$2.66 million | Q1 2022: -$2.86 million | Q2 2022: -$3.59 million | Q3 2022: -$3.44 million | Q1 2023: -$2.94 million | Q2 2023: -$2.56 million | Q3 2023: -$3.10 million | Q1 2024: -$2.78 million | Q2 2024: -$2.23 million | Q3 2024: -$2.35 million | Q1 2025: -$1.04 million | Q2 2025: -$1.23 million | Q3 2025: -$1.60 million.
- Over the full 10 years of available data (2016 to 2025), ENDRA Life Sciences Inc.'s Net Income Loss has declined by 153.2%.
- Historical annual values: Fiscal year 2025: -$7.03 million | Fiscal year 2024: -$11.51 million | Fiscal year 2023: -$10.06 million | Fiscal year 2022: -$13.18 million | Fiscal year 2021: -$11.23 million | Fiscal year 2020: -$11.73 million | Fiscal year 2019: -$13.31 million | Fiscal year 2018: -$9.80 million | Fiscal year 2017: -$5.38 million | Fiscal year 2016: -$2.78 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: